Antineoplastics
1
Reactions 1409 - 7 Jul 2012 Antineoplastics Skin eruptions in an elderly patient: case report A 65-year-old woman with multiple myeloma developed skin eruptions during treatment with antineoplastics [routes and outcomes not stated; not all dosages stated]. The woman received a 4-day infusion of dexamethasone (40 mg/body). Approximately 2 weeks later, her regimen was changed to bortezomib 1.3 mg/m 2 on days 1, 4, 8 and 11 of a 21-day cycle, plus dexamethasone 20 mg/body on the same day and the day after the bortezomib infusion. After four cycles of bortezomib plus dexamethasone, she developed a severe skin rash. The woman’s regimen was changed to lenalidomide plus dexamethasone. Two days later, she experienced a similar skin reaction. She was switched to melphalan plus prednisolone, but developed a similar skin eruption on the second day of treatment. She transferred herself to another hospital for a second opinion. Author comment: "Skin eruption is a common adverse reaction during bortezomib treatment. . . [B]oth lenalidomide plus dexamethasone and MP [melphalan plus prednisolone] therapies induced similar skin eruptions." Hua J, et al. A case of IgE-multiple myeloma presenting with a high serum Krebs von den Lungen-6 level. Leukemia Research 36: e107-e109, No. 5, May 2012. Available from: URL: http://dx.doi.org/10.1016/j.leukres.2012.02.007 - Japan 803072876 1 Reactions 7 Jul 2012 No. 1409 0114-9954/10/1409-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
Upload
vuongkhuong -
Category
Documents
-
view
216 -
download
4
Transcript of Antineoplastics
Reactions 1409 - 7 Jul 2012
Antineoplastics
Skin eruptions in an elderly patient: case reportA 65-year-old woman with multiple myeloma developed
skin eruptions during treatment with antineoplastics[routes and outcomes not stated; not all dosages stated].
The woman received a 4-day infusion of dexamethasone(40 mg/body). Approximately 2 weeks later, her regimenwas changed to bortezomib 1.3 mg/m2 on days 1, 4, 8 and11 of a 21-day cycle, plus dexamethasone 20 mg/body onthe same day and the day after the bortezomib infusion.After four cycles of bortezomib plus dexamethasone, shedeveloped a severe skin rash.
The woman’s regimen was changed to lenalidomide plusdexamethasone. Two days later, she experienced a similarskin reaction. She was switched to melphalan plusprednisolone, but developed a similar skin eruption on thesecond day of treatment. She transferred herself to anotherhospital for a second opinion.
Author comment: "Skin eruption is a common adversereaction during bortezomib treatment. . . [B]oth lenalidomideplus dexamethasone and MP [melphalan plus prednisolone]therapies induced similar skin eruptions."Hua J, et al. A case of IgE-multiple myeloma presenting with a high serum Krebsvon den Lungen-6 level. Leukemia Research 36: e107-e109, No. 5, May 2012.Available from: URL: http://dx.doi.org/10.1016/j.leukres.2012.02.007 -Japan 803072876
1
Reactions 7 Jul 2012 No. 14090114-9954/10/1409-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
